Stockreport

Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218

Vir Biotechnology, Inc.  (VIR) 
PDF SAN FRANCISCO, April 08, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious [Read more]